FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100090512> ?p ?o ?g. }

• W2100090512 endingPage "1259" @default.
• W2100090512 startingPage "1250" @default.
• W2100090512 abstract "High-dose therapy (HDT) followed by transplantation of autologous haemopoietic stem cells is frequently done as part of first-line therapy in young patients with high-risk aggressive B-cell lymphoma. We investigated whether HDT with cytotoxic agents identical to those used for conventional therapy followed by autologous stem-cell transplantation (ASCT) improved survival outcome compared with conventional chemotherapy when rituximab was added to both modalities.We did an open-label, randomised trial comparing conventional chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone) and rituximab (R-CHOEP-14) with dose-escalated sequential HDT and rituximab (R-MegaCHOEP) followed by repetitive ASCT in high-risk (age-adjusted International Prognostic Index [IPI] 2 or 3) patients aged 18-60 years with aggressive B-cell lymphoma. Eligible patients received radiotherapy for bulky, extranodal disease, or both. Randomisation (1:1) used the Pocock minimisation algorithm; patients were stratified by age-adjusted IPI factors, bulky disease, and centre. The primary endpoint was event-free survival. All analyses were done on the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT00129090.136 patients were randomly assigned to R-CHOEP-14 and 139 to R-MegaCHOEP. 130 patients in the R-CHOEP-14 group and 132 in the R-MegaCHOEP group were included in the intention-to-treat population. After a median of 42 months (IQR 29-59), 3-year event-free survival was 69·5% (95% CI 61·3-77·7) in the R-CHOEP-14 group and 61·4% (52·8-70·0) in the R-MegaCHOEP group (p=0·14; hazard ratio 1·3, 95% CI 0·9-2·0). All 128 evaluable patients treated with R-MegaCHOEP had grade 4 leucopenia, as did 48 (58·5%) of 82 patients with documented blood counts in the R-CHOEP-14 group. All 128 evaluable patients in the R-MegaCHOEP group had grade 3-4 thrombocytopenia, as did 26 (33·8%) of 77 patients in the R-CHOEP-14 group with documented blood counts. The most important non-haematological grade 3 or 4 adverse event was infection, which occurred in 96 (75·0%) of 128 patients treated with R-MegaCHOEP and in 40 (31·3%) of 128 patients treated with R-CHOEP-14.In young patients with high-risk aggressive B-cell lymphoma, R-MegaCHOEP was not superior to conventional R-CHOEP therapy and was associated with significantly more toxic effects. R-CHOEP-14 with or without radiotherapy remains a treatment option for these patients, with encouraging efficacy.Deutsche Krebshilfe." @default.
• W2100090512 created "2016-06-24" @default.
• W2100090512 creator A5002498295 @default.
• W2100090512 creator A5009950958 @default.
• W2100090512 creator A5014979722 @default.
• W2100090512 creator A5017002895 @default.
• W2100090512 creator A5018364683 @default.
• W2100090512 creator A5025964385 @default.
• W2100090512 creator A5027857526 @default.
• W2100090512 creator A5028397596 @default.
• W2100090512 creator A5036867361 @default.
• W2100090512 creator A5039235274 @default.
• W2100090512 creator A5039483120 @default.
• W2100090512 creator A5052598232 @default.
• W2100090512 creator A5064132655 @default.
• W2100090512 creator A5064401286 @default.
• W2100090512 creator A5067716137 @default.
• W2100090512 creator A5082456445 @default.
• W2100090512 creator A5087433936 @default.
• W2100090512 date "2012-12-01" @default.
• W2100090512 modified "2023-10-12" @default.
• W2100090512 title "Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)" @default.
• W2100090512 cites W1544519462 @default.
• W2100090512 cites W1819949687 @default.
• W2100090512 cites W1912693401 @default.
• W2100090512 cites W2011512040 @default.
• W2100090512 cites W2037796411 @default.
• W2100090512 cites W2038023916 @default.
• W2100090512 cites W2058015212 @default.
• W2100090512 cites W2059707463 @default.
• W2100090512 cites W2059990028 @default.
• W2100090512 cites W2074643584 @default.
• W2100090512 cites W2076668534 @default.
• W2100090512 cites W2085069027 @default.
• W2100090512 cites W2096470130 @default.
• W2100090512 cites W2103503232 @default.
• W2100090512 cites W2106459864 @default.
• W2100090512 cites W2118935462 @default.
• W2100090512 cites W2126779872 @default.
• W2100090512 cites W2131508403 @default.
• W2100090512 cites W2133505776 @default.
• W2100090512 cites W2135826545 @default.
• W2100090512 cites W2149617816 @default.
• W2100090512 cites W2155985551 @default.
• W2100090512 cites W2157717016 @default.
• W2100090512 cites W2159862107 @default.
• W2100090512 cites W2160305510 @default.
• W2100090512 cites W2161026651 @default.
• W2100090512 cites W2167237412 @default.
• W2100090512 cites W2339293928 @default.
• W2100090512 cites W2468279115 @default.
• W2100090512 cites W4205736005 @default.
• W2100090512 doi "https://doi.org/10.1016/s1470-2045(12)70481-3" @default.
• W2100090512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23168367" @default.
• W2100090512 hasPublicationYear "2012" @default.
• W2100090512 type Work @default.
• W2100090512 sameAs 2100090512 @default.
• W2100090512 citedByCount "200" @default.
• W2100090512 countsByYear W21000905122012 @default.
• W2100090512 countsByYear W21000905122013 @default.
• W2100090512 countsByYear W21000905122014 @default.
• W2100090512 countsByYear W21000905122015 @default.
• W2100090512 countsByYear W21000905122016 @default.
• W2100090512 countsByYear W21000905122017 @default.
• W2100090512 countsByYear W21000905122018 @default.
• W2100090512 countsByYear W21000905122019 @default.
• W2100090512 countsByYear W21000905122020 @default.
• W2100090512 countsByYear W21000905122021 @default.
• W2100090512 countsByYear W21000905122022 @default.
• W2100090512 countsByYear W21000905122023 @default.
• W2100090512 crossrefType "journal-article" @default.
• W2100090512 hasAuthorship W2100090512A5002498295 @default.
• W2100090512 hasAuthorship W2100090512A5009950958 @default.
• W2100090512 hasAuthorship W2100090512A5014979722 @default.
• W2100090512 hasAuthorship W2100090512A5017002895 @default.
• W2100090512 hasAuthorship W2100090512A5018364683 @default.
• W2100090512 hasAuthorship W2100090512A5025964385 @default.
• W2100090512 hasAuthorship W2100090512A5027857526 @default.
• W2100090512 hasAuthorship W2100090512A5028397596 @default.
• W2100090512 hasAuthorship W2100090512A5036867361 @default.
• W2100090512 hasAuthorship W2100090512A5039235274 @default.
• W2100090512 hasAuthorship W2100090512A5039483120 @default.
• W2100090512 hasAuthorship W2100090512A5052598232 @default.
• W2100090512 hasAuthorship W2100090512A5064132655 @default.
• W2100090512 hasAuthorship W2100090512A5064401286 @default.
• W2100090512 hasAuthorship W2100090512A5067716137 @default.
• W2100090512 hasAuthorship W2100090512A5082456445 @default.
• W2100090512 hasAuthorship W2100090512A5087433936 @default.
• W2100090512 hasConcept C126322002 @default.
• W2100090512 hasConcept C141071460 @default.
• W2100090512 hasConcept C143998085 @default.
• W2100090512 hasConcept C168563851 @default.
• W2100090512 hasConcept C203092338 @default.
• W2100090512 hasConcept C2776694085 @default.
• W2100090512 hasConcept C2776755627 @default.
• W2100090512 hasConcept C2778119113 @default.
• W2100090512 hasConcept C2778476033 @default.
• W2100090512 hasConcept C2779050716 @default.

• next